Shareholders' Deficit - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended				3 Months Ended				6 Months Ended
	Apr. 04, 2022	Jan. 06, 2022	Jan. 04, 2021	Jan. 01, 2021	Jan. 31, 2022	Mar. 31, 2021	Jan. 31, 2021	Sep. 30, 2020	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Sale of Stock [Line Items]
Payment for license agreement													$ 20,000	$ 0
Issuance of common shares as payment for assets										$ 253,779		$ 10,243
Proceeds from sale of common stock						$ 229,500							252,000	308,743
Equity Distribution Agreement aggregate amount															$ 400,000
Less: Share-based compensation expense attributable to non-controlling interests									$ 498		$ 540		$ 996	$ 900
Channel
Sale of Stock [Line Items]
Upfront cash payment	$ 35,000
Stock issued in acquisition, number of shares	493,254
Stock issued in acquisition	$ 58,747
Kleo
Sale of Stock [Line Items]
Ownership percentage															41.90%
Pfizer
Sale of Stock [Line Items]
Number of shares sold in transaction (in shares)					2,022,581
Proceeds from sale of stock					$ 350,000
Estimated fair value of shares issued					252,000
KU Leuven | License agreement | KU Leuven Agreement
Sale of Stock [Line Items]
Payment for license agreement					$ 3,000
Issuance of common shares as payment for assets (in shares)					15,340
Issuance of common shares as payment for assets					$ 1,779
Yale University | License agreement | Yale MoDE Agreement
Sale of Stock [Line Items]
Payment for license agreement							$ 1,000
Issuance of common shares as payment for assets (in shares)							11,668
Issuance of common shares as payment for assets							$ 1,000
Moda Pharmaceuticals LLC | License agreement | Moda Agreement
Sale of Stock [Line Items]
Payment for license agreement				$ 2,700
Issuance of common shares as payment for assets (in shares)				37,836
Issuance of common shares as payment for assets				$ 3,243
BioShin Limited
Sale of Stock [Line Items]
Conversion rate of preferred stock to common stock per agreement (in shares)		0.080121
Repurchase of preferred shares in consolidated subsidiary (in shares)		1,232,629
Common Shares
Sale of Stock [Line Items]
Issuance of common shares as payment for assets (in shares)										2,037,921		110,998
Issuance of common shares as payment for assets										$ 253,779		$ 10,243
Common stock issued (shares)												4,037,204
Issuance of common shares as part of acquisition (in shares)									493,254			115,836
Repurchase of preferred shares in consolidated subsidiary (in shares)										1,232,629
Kleo
Sale of Stock [Line Items]
Shares of common stock exchanged for each share of acquiree			0.007
Issuance of common shares as part of acquisition (in shares)			115,836
BioShin 2020 Equity Incentive Plan
Sale of Stock [Line Items]
Requisite service period of award (in years)								3 years
Public offering
Sale of Stock [Line Items]
Common stock issued (shares)						2,686,409
Issuance price per share (in dollars per share)						$ 76.00						$ 76.00
Proceeds from sale of common stock						$ 199,500
Underwriting discounts and commissions						4,167
Other offering expenses						$ 500
Over-allotment option
Sale of Stock [Line Items]
Common stock issued (shares)						402,961
Proceeds from sale of common stock						$ 30,000
Underwriting discounts and commissions						$ 625
Equity Distribution Agreement
Sale of Stock [Line Items]
Common stock issued (shares)									0		0		0	939,328
Proceeds from sale of common stock														$ 78,743
BioShin Preferred Shares | Series A preferred shares
Sale of Stock [Line Items]
Preferred stock issued and sold (in shares)								15,384,613
Shares issued price per share								$ 3.90
Proceeds from shares issued								$ 60,000